Meridian Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Meridian Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,534	Closed	-$1.01M	–	85
2022 Q2	$1.01M	Buy	3,534 +3	+0.1%	+$803	0.69%	37
2022 Q1	$921K	Buy	3,531 +133	+4%	+$31.6K	1.37%	21
2021 Q4	$784K	Buy	3,398 +509	+18%	+$99K	0.53%	42
2021 Q3	$521K	Buy	2,889 +62	+2%	+$12.1K	0.35%	54
2021 Q2	$556K	Buy	2,827 +113	+4%	+$23.6K	0.38%	52
2021 Q1	$598K	Buy	2,714 +183	+7%	+$40.2K	0.45%	48
2020 Q4	$599K	Buy	+2,531	New	+$581K	0.46%	43

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meridian Financial Partners's VRTX Position: Q3 2022 in Review

Meridian Financial Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 3,534 shares — an estimated $1.01M sold.

Meridian Financial Partners first reported a position in VRTX in Q4 2020 and held it in 7 quarters. The position peaked at $1.01M in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Meridian Financial Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Meridian Financial Partners sold 3,534 Vertex Pharmaceuticals shares in Q3 2022, an estimated $1.01M.
Meridian Financial Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Meridian Financial Partners's Vertex Pharmaceuticals position peaked at $1.01M in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Meridian Financial Partners's 13F filing for Q3 2022, filed 24 Oct 2022.